Ophthalmic Drug Market in China 2021
The ophthalmic drug market in China in terms of revenue is set to grow by US$ 6 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.9% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for ophthalmic drug. The China ophthalmic drug market is segmented on the basis of incidence. By incidence, it is categorized into allergic conjunctivitis, bacterial conjunctivitis, blepharitis, dry eye disease, glaucoma, myopia, and non-infectious uveitis.
The report has profiled some of the key players of the market such as Novartis International AG, Santen Pharmaceutical Co. Ltd., Shenyang Xingqi Pharmaceutical Co. Ltd., URSAPHARM Arzneimittel GmbH.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ophthalmic drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Incidence: allergic conjunctivitis, bacterial conjunctivitis, blepharitis, dry eye disease, glaucoma, myopia, and non-infectious uveitis
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China ophthalmic drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the ophthalmic drug market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for ophthalmic drug. The China ophthalmic drug market is segmented on the basis of incidence. By incidence, it is categorized into allergic conjunctivitis, bacterial conjunctivitis, blepharitis, dry eye disease, glaucoma, myopia, and non-infectious uveitis.
The report has profiled some of the key players of the market such as Novartis International AG, Santen Pharmaceutical Co. Ltd., Shenyang Xingqi Pharmaceutical Co. Ltd., URSAPHARM Arzneimittel GmbH.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ophthalmic drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Incidence: allergic conjunctivitis, bacterial conjunctivitis, blepharitis, dry eye disease, glaucoma, myopia, and non-infectious uveitis
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China ophthalmic drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the ophthalmic drug market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. OPHTHALMIC DRUG MARKET BY INCIDENCE
4.1 Allergic Conjunctivitis
4.2 Bacterial Conjunctivitis
4.3 Blepharitis
4.4 Dry Eye Disease
4.5 Glaucoma
4.6 Myopia
4.7 Non-Infectious Uveitis
5. COMPANY PROFILES
5.1 Novartis International AG
5.2 Santen Pharmaceutical Co., Ltd.
5.3 Shenyang Xingqi Pharmaceutical Co., Ltd.
5.4 URSAPHARM Arzneimittel GmbH
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. OPHTHALMIC DRUG MARKET BY INCIDENCE
4.1 Allergic Conjunctivitis
4.2 Bacterial Conjunctivitis
4.3 Blepharitis
4.4 Dry Eye Disease
4.5 Glaucoma
4.6 Myopia
4.7 Non-Infectious Uveitis
5. COMPANY PROFILES
5.1 Novartis International AG
5.2 Santen Pharmaceutical Co., Ltd.
5.3 Shenyang Xingqi Pharmaceutical Co., Ltd.
5.4 URSAPHARM Arzneimittel GmbH
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
